Venlafaxine Hydrochloride
Product Images NDC 58118-0335

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 58118-0335). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (719c77d6 C5bc 4d70 89b1 E84f1bf4b9dd 01)

This text appears to be a table that lists certain drugs and their interactions with other drugs in individuals who are either poor metabolizers (PM) or extensive metabolizers (EM) of the enzyme CYP2D6. The drugs listed include Ethanol, Diazepam, Cimetdine, Ketoconazole, Indinavir, Metoprolol, Imipramine, and Lithium. The table also includes the analyte Venlafaxine and some PK (pharmacokinetic) values such as Cmax and AUC, along with their recommended dosage adjustment and usage instructions.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (719c77d6 C5bc 4d70 89b1 E84f1bf4b9dd 02)

This text appears to be a list of interacting drugs with their respective analyte PKFold change and recommendations on concomitant use. The drugs listed include ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, and lithium. The recommendations on concomitant use range from avoiding concomitant use to no dose adjustment needed with some clinical significance unknown.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (719c77d6 C5bc 4d70 89b1 E84f1bf4b9dd 03)

This pertains to dosing recommendations based on the patient's special population, hepatic and renal conditions, CYP2D8 polymorphism, age, gender, and analytes such as venlafaxine. It suggests reducing dose by either 25% or 50%, individualizing the dosing and other instances not requiring dose adjustment. However, the provided text lacks complete and coherent information, making it difficult to establish the context and meaning of some of the abbreviations and terms mentioned, therefore further explanation or context for specific recommendations may be necessary.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (719c77d6 C5bc 4d70 89b1 E84f1bf4b9dd 04)

The text contains the names "eHCI", "H4C0 C", and "venlafaxine hydrochloride". It is possible that this text is referring to the chemical compound venlafaxine hydrochloride. However, the other two phrases ("eHCI" and "H4C0 C") do not seem to provide any meaningful context or information. Overall, this text is not very useful due to its ambiguity.*

FDA Label Image

Venlafaxine Er 75mg

This is information about the wholesale of Venlafaxine ER 75mg Capsules. It includes details such as the NDC code, quantity of 30, GTIN, manufacturing lot number, and expiration date of September 2021. The manufacturer is listed as Wyeth Pharmaceuticals, and the product appears to be based in the United States, in Pennington, NJ. However, the last line of text is not legible, so its meaning is unclear.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.